Will the Mid-Sized European Rx Company Survive?
Executive Summary
Given the costs and scientific requirements of the international drug business, mid-sized European companies should restructure themselves as NRDOs (No Research, Development Only companies), partnering for new products with biotech companies, says Fred Frank of Lehman Brothers.